Available On-Demand
Graves’ disease (GD) is caused by circulating autoantibodies that stimulate the TSH receptor (TSHR), leading to unregulated production and secretion of thyroid hormones. Measurement of TSHR antibodies (TRAb) in patient serum is a sensitive tool to assess GD. In addition to diagnosis, there are several other clinical implications where TRAb measurement is valuable. Functionally, TRAb can be divided into two main categories – thyroid-stimulating antibodies (TSAb, TSI) and thyroid-blocking antibodies (TBAb, TBI) – that can (co)exist in patients with GD.
In this webinar, we will discuss:
- Clinical and pathophysiological aspects of GD, including Graves’ orbitopathy
- TRAb nomenclature
- Different types of TRAb bindings and functional assays
- Clinical application of the TSI assay
Key learning objectives
- Explain the clinical and pathophysiological aspects of Graves’ disease, including Graves’ orbitopathy
- Determine the different types of TRAb bindings and functional assays
- Discuss the clinical application of the TSI assay
Who should attend
- Clinicians
- Laboratorians
- Specialists
- Government decision makers
- Healthcare professionals
Accreditation statement
SelectScience is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.
Presenters
Willem A. Dik
Medical immunologist
Erasmus University Rotterdam, Erasmus Medical Center
Dr. Willem Dik is a laboratory specialist in medical immunology at Erasmus MC, University Medical Center in Rotterdam. His research aims to identify cellular and molecular mechanisms underlying (chronic) inflammatory processes, associated tissue remodeling and organ dysfunction. He has co-authored more than 175 published articles, and pursues a strong focus on ocular diseases, immune dysregulation/immunodeficiency disorders, sarcoidosis, and thyroid autoimmune disease.
Dora Wells
Editorial Team
SelectScience
